AstraZeneca held talks with Bristol Myers Squibb on $400 billion megadeal, source says
The preliminary discussions come as Bristol Myers seeks new growth avenues while AstraZeneca continues to expand on the back of strong oncology sales.
The preliminary discussions come as Bristol Myers seeks new growth avenues while AstraZeneca continues to expand on the back of strong oncology sales.